Private Advisor Group LLC acquired a new position in shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 14,150 shares of the company’s stock, valued at approximately $187,000.
Other hedge funds also recently added to or reduced their stakes in the company. Sphera Funds Management LTD. raised its holdings in Apellis Pharmaceuticals by 91.8% during the third quarter. Sphera Funds Management LTD. now owns 212,470 shares of the company’s stock worth $3,778,000 after purchasing an additional 101,667 shares in the last quarter. Opaleye Management Inc. raised its holdings in Apellis Pharmaceuticals by 41.5% during the third quarter. Opaleye Management Inc. now owns 375,000 shares of the company’s stock worth $6,667,000 after purchasing an additional 110,000 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $283,000. Prudential Financial Inc. increased its holdings in shares of Apellis Pharmaceuticals by 36.5% in the 3rd quarter. Prudential Financial Inc. now owns 184,130 shares of the company’s stock valued at $3,274,000 after acquiring an additional 49,230 shares during the period. Finally, MetLife Investment Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $477,000. 53.89% of the stock is currently owned by institutional investors.
In other Apellis Pharmaceuticals news, major shareholder Morningside Venture Investment bought 441,176 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were acquired at an average cost of $17.00 per share, with a total value of $7,499,992.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 9.30% of the company’s stock.
A number of equities analysts have recently commented on APLS shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $53.00 target price on shares of Apellis Pharmaceuticals in a report on Thursday, December 20th. Citigroup lifted their target price on shares of Apellis Pharmaceuticals from $34.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, December 6th. B. Riley started coverage on shares of Apellis Pharmaceuticals in a report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 target price on the stock. Zacks Investment Research raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 4th. Finally, JPMorgan Chase & Co. cut shares of Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $34.00 target price on the stock. in a report on Wednesday, January 23rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $39.33.
Apellis Pharmaceuticals Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Recommended Story: Momentum Investing
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.